The Public’s Distrust of Biotech Is Deepening. Commercialization May Be to Blame.
November 6, 2017
(Undark) – Harvard medical geneticist Robert C. Green, reflective, cautious, and as decent as a scientist can sound, took to television last month to make people aware of an open trial at the Brigham and Women’s Hospital, which uses genomic sequencing to screen for variants that can predict 1,800 genetic conditions in newborns. The cutting-edge study foreshadows what genetic science might bestow to human health, but the more interesting takeaway is that the failure of the study to connect with the public — very few are enrolling — may signify a deepening distrust of biotech.